News Release
Home
News Release
- 2021.10.14 lR Information
- Notification Regarding Application for Selection of “Prime Market” Under the New Market Segments
- 2021.10.14 lR Information
- Notification Regarding Concerning the Decision of Matters Relating to Acquisition of Company’s Own Shares
- 2021.10.14 lR Information
- FY02/2022 Q2 Results Earnings Release Presentation
- 2021.10.04 Other
- Hisamitsu Pharmaceutical Online Sales “Hisamitsu® Iki-Iki Online” Announcement of Starting Pharmaceutical Product Sales
- 2021.09.21 Other
- Announcement of Investment in GAIA Biomedicine, a Bio-Venture from Kyushu University in Japan
- 2021.09.17 Management and Personnel
- Announcement regarding Establishment of “the 7th Medium-term Management Policy” (Presentation Material)
- 2021.09.17 Management and Personnel
- Announcement regarding Establishment of “the 7th Medium-term Management Policy”
- 2021.08.27 Other
- Notice regarding Providing Relief Supplies in Response to The Torrential Rains in August 2021
- 2021.08.12 Other
- Notification of Hisamitsu Pharmaceutical Co., Inc. receiving Administrative Disposition from Saga Prefecture
- 2021.07.30 Ethical Drugs
- Notification of Transfer of Marketing Rights for ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis
- 2021.07.26 lR Information
- Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
- 2021.07.08 lR Information
- FY02/2022 Q1 Results Earnings Release Presentation
- 2021.07.08 lR Information
- Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
- 2021.05.28 Other
- Signing of Partnership Agreement with Saga Prefecture and Saga Sports Association Promotion of “SAGA Sports Pyramid Design”
- 2021.05.28 lR Information
- Approach to and Policy on Reduction of Investment Unit, etc.
- 2021.05.27 Management and Personnel
- Executive Appointments
- 2021.05.19 Ethical Drugs
- Notification of marketing of ZICTHORU® Tapes for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch)
- 2021.05.18 Other
- Salonpas® Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Fifth Consecutive Year
- 2021.04.27 Research and Development
- Notification of the results of the Phase Ⅲ clinical study of HP-5070 in Japan (primary palmar hyperhidrosis treatment drug)
- 2021.04.08 lR Information
- FY02/2021 Q4 Results Earnings Release Presentation
- 2021.04.08 Management and Personnel
- Executive Appointments
- 2021.04.02 Other
- Contributions to The Japan Olympic Committee (JOC) and The Japan Paralympic Committee (JPC)
- 2021.03.23 Ethical Drugs
- Notification of approval for manufacturing and marketing approval of ZICTHORU® TAPES for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch, development code: HP-3150)
- 2021.03.23 lR Information
- Notice regarding Revision of Earnings Forecast
- 2021.02.24 Subsidiaries and Affiliated Companies
- Noven Pharmaceuticals, Inc. press release : Noven submits New Drug Application for INVESTIGATIONAL dextroamphetamine transdermal system for ADHD
- 2021.02.12 Other
- Notice regarding The Decision to Contribute to Supporting Organizations in FY 2020 through Hisamitsu Pharmaceutical Co., Inc. Hot Heart Club
- 2021.01.20 Ethical Drugs
- Notice regarding Obtaining Approval of Partial Change of Approved Matters of “Mohrus® Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
- 2021.01.13 lR Information
- FY02/2021 Q3 Results Earnings Release Presentation
- 2021.01.04 Research and Development
- Notification of the commencement of the Phase III clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)
